William Blair analyst Myles Minter maintained an Outperform rating and $105 price target on Karuna Therapeutics after the company disclosed the effect size from its positive Phase II trial of KarXT for the treatment of schizophrenia, which surpassed the analyst's expectations and "exemplifies the therapy's best-in-class risk/benefit profile." Minter called it "the first truly novel antipsychotic in over 30 years that possesses efficacy in the range of the atypical antipsychotics without the compliance-restricting adverse effects triggered by dopamine receptor antagonism." In afternoon trading, shares of Karuna are higher by 17.1% to $86.84.

New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).